Curriculum Vitae

Name	**Shiva Malek, Ph.D.**	
Current Position & Affiliation	**Vice President and Head of Discovery Oncology Genentech Research and Early Development, South San Francisco, CA Adjunct Professor, Department of Biochemistry and Biophysics School of Medicine, UCSF**	
Country	**USA**	

Educational Background

Ph.D., Biochemistry, University of California, San Diego, 2000
M.S., Chemistry, University of California, Irvine, 1995
B.S., Biochemistry, University of California, Los Angeles, 1993

Professional Experience

Vice President and Head of Discovery Oncology
Genentech Research and Early Development, South San Francisco, CA

Adjunct Professor, Department of Biochemistry and Biophysics
School of Medicine, UCSF (2018-current)

Vice President, Discovery Oncology (2021-current)
Executive Director, Discovery Oncology (2019-2021)
Director, Discovery Oncology (2016-2019)
Associate Director, Discovery Oncology (2014-2016)
Associate Director, Biochemical and Cellular Pharmacology (2012-2014)
Senior Fellow, Discovery Oncology (2020-present)
Principal Scientist, Discovery Oncology (2015-2020)
Senior Scientist, Biochemical and Cellular Pharmacology (2010-2014)
Scientist, Biochemical and Cellular Pharmacology (2006-2010)

Professional Organizations

2022-2024 Keystone Symposia, Scientific Advisory Board Member
2021-2024 AACR Women in Cancer Research, Board Council Member
2019-current Cancer Molecular Therapeutics Research Association, Board Member
2020-current Genentech Diversity and Inclusion Committee, Board Member
2014-2017-Project Scientist (An education non-profit devoted to addressing the challenges and disadvantages women and girls face in STEM), Board Member
2020 HHMI Investigator Competition, grant reviewer
2021 Oncode Institute (established in 2017 by the Dutch government and the Dutch Cancer Society), external grant reviewer

Main Scientific Publications

Chang MT, Shanahan F, Nguyen TTT, Staben ST, Gazzard L, Yamazoe S, Wertz IE, Piskol R, Yang A, Zora Modrusan, Haley B, Evangelista M, **Malek S**, Foster SA, *, Ye X, * (2021). Identifying transcriptional programs underlying cancer drug response with TraCe-seq. Nature Biotechnology, in press

Huestis MP, Durk MR, Eigenbrot C, Gibbons P, Hunsaker TL, La H, Leung DH, Liu W, **Malek S**, Merchant M, Moffat JG, Muli CS, Orr CJ, Parr BT, Shanahan F, Sneeringer CJ, Wang W, Yen I, Yin J, Rudolph J, Siu M (2021). Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. ACS Med Chem Lett 12(5):791-797.

Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW*, **Malek S.*** (2021). ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature. 2021 May 5. doi: 10.1038/s41586-021-03515-1. Online ahead of print.
Scientific Press: Research Watch, ARAF Mutations Limit Response to RAF Dimer Inhibition, Cancer Discovery May 2021.

Rudolph J, Settleman J, **Malek S.*** (2021). Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming Resistance. Cancer Discovery 11(4):815-821.

Huestis MP, Dela Cruz D, DiPasquale AG, Durk MR, Eigenbrot C, Gibbons P, Gobbi A, Hunsaker TL, La H, Leung DH, Liu W, **Malek S**, Merchant M, Moffat JG, Muli CS, Orr CJ, Parr BT, Shanahan F, Sneeringer CJ, Wang W, Yen I, Yin J, Siu M, Rudolph J. (2021). Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. J Med Chem. 64(7):3940-3955.

Pham TH, Hagenbeek TJ, Lee H-J, Li J, Rose CM, Lin E, Yu M, Martin SE, Piskol R, Lacap JL, Sampath D, Pham VC, Modrusan Z, Lill JR, Klijn C, **Malek S**, Chang MT, Dey A (2020). Machine learning and chemico-genomics approach defines and predicts cross-talk of Hippo and MAPK pathways. Cancer Discov. 2020 Nov 18;CD-20-0706. doi: 10.1158/2159-8290.CD-20-0706.

Liau NPD, Venkatanarayan A, Quinn JG, Phung W, **Malek S**, Hymowitz SG, Sudhamsu J (2020). Dimerization Induced by C-Terminal 14-3-3 Binding Is Sufficient for BRAF Kinase Activation. Biochemistry. 2020 Oct 2. doi: 10.1021/acs.biochem.0c00517.

Moore A, Rosenberg S, McCormick F, **Malek S*** (2020). RAS-targeted therapies: is the undruggable drugged? Nature Reviews Drug Discovery, doi: 10.1038/s41573-020-0068-6.

Liau NPD, Wendorff TJ, Quinn JG, Steffek M, Phung W, Liu P, Tang J, Irudayanathan FJ, Izadi S, Shaw AS, **Malek S**, Hymowitz SG, Sudhamsu J (2020). Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. Nat Struct Mol Biol. 27(2):134-141.

Dorstyn L, Tvorogov D, **Malek S**, Robinson N (2020). The 9th Barossa Meeting: Cell Signalling in Cancer Medicine. Cell Death Dis. 11(3):162.

Venkatanarayan A, **Malek S*** (2019). Partners in Crime: Clandestine Operations among RAS-RAF Accomplices in Promoting Tumorigenesis. Mol Cell. 76(6):853-855.

Yen I, Shanahan F, Merchant M, Orr C, Hunsaker T, Durk M, La ., Zhang X, Martin S, Lin E, Chan J, Yu Y, Amin D, Neve R, Gustafson A, Foster S, Rudolph J, Klijn C *, **Malek S*** (2018). Pharmacological induction of RAS-GTP levels confers RAF kinase dependency in KRAS mutant tumors. Cancer Cell, 34: 611-625.

Scientific Press: Interviewed by Jim Hartley for the RAS Dialogue-NCI RAS Initiative; https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2018/shiva-malek

Hymowitz S. and **Malek S*** (2018). Targeting the MAPK Pathway in RAS Mutant Cancers. Cold Spring Harb Perspect Med. 8(11). pii: a031492.